一项关于BPX-601 CAR T细胞疗法在治疗抵抗性复发并已扩散的前列腺癌成年患者中的1期研究
一项关于BPX-601(一种抗PSCA CAR T细胞药物产品)在复发/难治性转移性去势抵抗性前列腺癌中进行的1期、开放标签、剂量递增研究
This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies.
The study is looking at:
- What side effects BPX-601 might cause
- What is the best dose of BPX-601
- How well BPX-601 may work to destroy prostate cancer
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Clinical Trials Administrator
- 电话号码:844-734-6643
- 邮箱:clinicaltrials@regeneron.com
学习地点
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory Winship Cancer Institute
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- 招聘中
- John Theurer Cancer Center
-
-
Oregon
-
Portland、Oregon、美国、97213
- 招聘中
- Providence Portland Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of hormone-refractory adenocarcinoma of the prostate without pure small cell carcinoma
- Metastatic, Castration-Resistant Prostate Cancer (mCRPC) with PSA value at screening ≥4 ng/mL that has progressed within 6 months prior to screening, as defined in the protocol
- Has received ≥2 lines prior systemic therapy approved in the metastatic and/or castration-resistant setting [in addition to Androgen Deprivation Therapy (ADT)] including at least 1 second-generation anti-androgen therapy (eg, abiraterone, enzalutamide, apalutamide, or darolutamide)
- Has had either orchiectomy OR is on Luteinizing Hormone-Releasing Hormone (LHRH) agonist or antagonist therapy with serum testosterone <50 ng/dL AND agrees to stay on LHRH agonist or antagonist therapy during the study
Key Exclusion Criteria:
- Structurally unstable bone lesions suggesting impending fracture
- Clinical or radiographic evidence of deep vein thrombosis, pulmonary embolism, or other known thromboembolic event that has not been definitively treated. Participants with prior history of coagulopathy must be on low-molecular weight heparin prophylaxis or prophylactic dose of oral anticoagulant and asymptomatic within 4 weeks of the planned BPX-601 infusion
- Inadequate renal function defined by creatinine clearance <60 mL/min calculated by 24-hour urine collection or using the Cockcroft-Gault formula
- Inadequate hepatic function defined by Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >2.5 × ULN or >5 × ULN, if liver metastases, and/or total bilirubin >1.5 × ULN, as described in the protocol
- Inadequate bone marrow function defined by Absolute Neutrophil Count (ANC) <1.5 × 10^9/L or platelet count <150 × 10^9/L. At least 7 days must have passed since the last dose of filgrastim (or 14 days since the last dose of pegfilgrastim) and at least 7 days must have passed since the last platelet transfusion at the time of ANC or platelet count.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:BPX-601单药治疗
|
Administered per protocol |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
治疗中出现的不良事件(TEAEs)的发生情况
大体时间:最长4年
|
最长4年
|
|
剂量限制性毒性(DLTs)的发生
大体时间:截至第28天
|
截至第28天
|
|
特别关注不良事件(AESIs)的发生
大体时间:最长4年
|
最长4年
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
客观缓解
大体时间:最多4年
|
最多4年
|
|
|
缓解持续时间 (DoR)
大体时间:最长4年
|
最长4年
|
|
|
疾病控制
大体时间:最长 4 年
|
最长 4 年
|
|
|
前列腺特异性抗原(PSA50)应答减少≥50%
大体时间:最长4年
|
最长4年
|
|
|
PSA90 应答
大体时间:最长4年
|
最长4年
|
|
|
Manufacturing feasibility of BPX-601
大体时间:Up to 4 years
|
Determination of the feasibility of manufacturing BPX-601 is measured by the percent of leukapheresis products collected that are able to be manufactured and released for infusion |
Up to 4 years
|
合作者和调查者
调查人员
- 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- BPX-601-PSA-2540
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD 共享时间框架
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共享访问标准
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.